Loading...
After reviewing available data on the risks and benefits associated with various nonsteroidal anti-inflammatory drugs (NSAIDs) and holding related public meetings in February 2005, the FDA issued a public health advisory on April 7. The key components of the FDA advisory are:
a request that valdecoxib (Bextra), a highly selective cyclooxygenase (COX)-2 inhibitor, be withdrawn from the market, because of inadequate long-term data to establish its cardiovascular safety, evidence of short-term cardiovascular risk after coronary artery bypass surgery, reports of serious and potentially life-threatening skin reactions linked to the drug, and a lack of demonstrated advantages over other NSAIDs. Bextra's manufacturer has agreed to withdraw the drug…